Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Gets CE Mark for Intestinal Parasites Test

NEW YORK – Finnish molecular diagnostics company Mobidiag said today that it has received CE-IVD marking for its Novodiag Stool Parasites test for the detection of intestinal parasites from stool samples.

The Novodiag Stool Parasites syndromic test combines real-time PCR and microarray technologies to detect more than 95 percent of intestinal parasites, the firm said. Its test detects the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples.

Espoo, Finland-based Mobidiag said that its test is designed to run on demand using its automated Novodiag platform, which allows direct analysis of a patient sample in a disposable cartridge. The stool parasites test provides results in 90 minutes with less than five minutes hands-on time, and is suitable for use in laboratories and hospitals.

"Parasitic diseases contribute significantly to the burden of infectious diseases worldwide and current diagnostic methods such as microscopy are labor-intensive and require a high level of skill," Mobidiag CEO Tuomas Tenkanen said in a statement.

As the fourth test on the company's platform, Novodiag Stool Parasites joins Novodiag C. difficile, Novodiag Bacterial GE+, and Novodiag CarbaR+ among the company's products.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.